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proliferative retinopathy, but with various stages of renalAssociation between high von Willebrand factor levels and the
involvement, which ranged from no microalbuminuria, despiteThr789Ala vWF gene polymorphism but not with nephropathy
a mean duration of diabetes of 31 years, to advanced nephropa-in type I diabetes.
thy (GENEDIAB Study): Thr789Ala (Rsa I), M2/M1 (Msp I)Background. A genetic susceptibility for diabetic kidney dis-
ease is suspected since diabetic nephropathy occurs in only 30 (intron 19), and Ala1381Thr (Hph I). Plasma vWF and factor
to 40% of type I diabetic patients. As elevated von Willebrand VIII (F VIII) levels were also measured in this population.
factor (vWF) plasma concentrations have been reported to Results. Plasma vWF and F VIII levels were increased in
precede the development of microalbuminuria in type I diabe- diabetic subjects with nephropathy (P , 0.001) or with coro-
tes, we addressed a possible implication of vWF as a genetic nary heart disease (CHD; P , 0.001), but there was no interac-
determinant for diabetic nephropathy. tion of both conditions on plasma levels. The Msp I polymor-
Methods. Three known vWF gene polymorphisms were ge- phism (M2/M1) was weakly associated with nephropathy
notyped in a group of 493 type I diabetic subjects, all showing (P 5 0.04), but this association was not more significant when
other risk factors were used in a logistic regression analysis.
The vWF Thr789Ala polymorphism was associated with CHD
Key words: genetics, diabetic renal disease, CHD, von Willebrand (P 5 0.002) and with plasma vWF levels. Logistic regression
factor. analysis indicated an independent and codominant effect of
the Thr789Ala polymorphism on CHD, but not on nephropa-1 The two last authors were equally responsible for this work. thy, with a maximal risk for Ala/Ala homozygotes (OR 5 4.2,2 Gene´tique de la Nephropathie DIABe´tique (GENEDIAB) Study
95% CI, 1.8 to 9.9, P 5 0.0008).Group: Philippe Passa and Abderamane Bouallouche (Hoˆpital Saint-
Conclusion. It is unlikely that polymorphisms in the vWFLouis, Paris), Michel Rodier, Florence Galtier, and Jacques Bringer
(Niˆmes-Montpellier), Michel Marre and Be´atrice Bouhanick (Angers, gene contribute to the risk for nephropathy in type I diabetic
coordinating clinical center), Caroline Sert and Andre´ Grimaldi (Hoˆpi- patients. However, the Thr789Ala polymorphism might affect
tal La Pitie´, Paris), Laurent Dusselier, The´re`se Crea, and Pierre Drouin the risk for CHD in this population through modulation of
(Nancy), Zoubida Kahal and Dominique Simon (Cre´teil), Lucy Chail- plasma vWF levels.
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physiology of diabetic kidney disease, was proposed to antihypertensive treatment); stage 2, incipient nephropa-
thy (microalbuminuria, plasma creatinine , 150 mmol/L,elucidate the molecular basis of diabetic nephropathy.
Endothelial dysfunction and a prothrombotic state are no antihypertensive treatment); stage 3, established ne-
phropathy (past or present macroalbuminuria, plasmafrequently observed in diabetic patients [5], especially
when they present a microvascular disease. Synthesized creatinine , 150 mmol/L, with or without antihyperten-
sive treatment); and stage 4, advanced nephropathy (pastby the endothelium and the megakaryocytes, von Wille-
brand factor (vWF) is a highly multimerized glycoprotein or present macroalbuminuria and plasma creatinine $ 150
mmol/L, with or without antihypertensive treatment orthat promotes platelet adhesion and aggregation at a high
shear rate, while also acting as a carrier of coagulation patients on renal replacement therapy). The patients
were staged for CHD as no CHD, angina pectoris, orfactor VIII (F VIII) [6]. Because of this dual function
of vWF in hemostasis, the vWF gene, located on chromo- myocardial infarction from a standardized questionnaire
for angina pectoris, and from past or present myocardialsome 12 (12p12-pter), is a good candidate for the devel-
opment of microvascular and macrovascular complica- infarction, documented by either the patient records
and/or the presence of a pathological Q wave on a cur-tions in diabetes. Indeed, elevated vWF plasma levels
have been reported in type I diabetes complicated with rent electrocardiogram (using Minnesota code 1.1.1. to
1.3.6. for Q wave identification) [17]. Plasma total choles-nephropathy [7, 8] or with retinopathy [9, 10]. Further-
more, vWF has been identified as a risk factor for recur- terol was measured enzymatically [18]. Smoking habits
were obtained from questionnaires.rent myocardial infarction in the general population
[11, 12]. This observation reinforces the rationale for Control subjects were 359 age- and sex-matched healthy
persons participating in a prospective study on insulinstudying the potential relationship between vWF levels
and nephropathy in type I diabetes, because the relative resistance and cardiovascular disease in the French gen-
eral population [19].risk for coronary heart disease (CHD) is 10-fold higher
in type I diabetic patients with proteinuria compared
von Willebrand factor and F VIII assayswith those without the disease [13]. As elevated vWF
plasma concentrations have been also reported to pre- von Willebrand factor and F VIII antigens (vWF:Ag
and F VIII:Ag) levels in plasma were both measured bycede the development of microalbuminuria in type I
diabetes [14, 15], we addressed a possible implication of an enzyme-linked immunosorbent assay (ELISA) on the
frozen heparinized plasma of 475 patients. Data for 18vWF as a genetic determinant.
The purpose of this study was to evaluate the possible patients of the original cohort could not be presented
because frozen heparinized plasma was lacking or theimplication of vWF in the occurrence of nephropathy in
type I diabetic patients. F VIII and vWF plasma levels plasma measurements did not work. vWF plasma levels
were determined on a BioMerieux (Lyon, France) Vidaswere measured in a population of type I diabetic subjects,
all selected on the basis of severe retinopathy, but with automate using reagents provided by the manufacturer.
F VIII plasma levels were measured using a kit fromvarious degrees of renal involvement [16]. The associa-
tion between the vWF plasma concentration and vWF Diagnostica Stago (Chilly-Mazarin, France). All assays
were performed on three different plasma dilutions.genotypes was then assessed through the analysis of
three vWF gene polymorphisms located in two function-
von Willebrand factor polymorphisms analysisally important regions of the vWF molecule, which medi-
ate its interaction with F VIII or platelets. The three vWF gene polymorphisms were analyzed by
polymerase chain reaction (PCR)- restriction fragment
length polymorphism (RFLP), as previously described
METHODS
[20, 21]. PCR was carried out using Taq Gold from Per-
Patients kin Elmer-Cetus in the presence of the buffer supplied
by the manufacturer containing 1.5 mmol/L MgCl2, 200A cross-sectional multicenter study (GENEDIAB
Study) was conducted in 16 diabetic clinics in France mmol/L dNTPs, 0.1 mmol/L of each primer, and 50 ng
DNA (extracted from peripheral blood lymphocytes byand in Belgium, as detailed in Marre et al [16]. The
selection criteria were type I diabetes (that is, ketosis- a standard protocol). After an initial denaturation-Taq
Gold activation step of 948C for 12 minutes, “touch-prone diabetes requiring insulin treatment within one
year of diagnosis) before the age of 35 years and past down” PCR amplification was performed as follows:
948C for 2 minutes, 748C for 15 seconds, 948C for 1or present proliferative diabetic retinopathy. Eligible pa-
tients were recruited consecutively over one year. Patient minute, 708C for 15 seconds, 948C for 1 minute, 658 for
10 seconds, 728C for 15 seconds and then 30 cycles ofcharacteristics were collected as described earlier [16].
The different stages of diabetic nephropathy were de- 948C for 20 seconds, 508C for 20 seconds, 728C for 30
seconds, and 728C for 2 minutes. The following primerfined as follows: stage 1, no nephropathy (normal urinary
albumin excretion, plasma creatinine , 150 mmol/L, no sets were used: 59-GAAAACTGAAGGGCAGGCAC
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Table 1. Plasma levels of von Willebrand factor (vWF) and factor VIII (F VIII) according to stages of nephropathy
and of coronary heart disease (CHD)
Nephropathy Absent Incipient Established Advanced Totals
No CHD (N5136) (N596) (N5105) (N584) (N5421)
vWF (IU/dL) 139 (38–415) 144 (64–711) 160 (71–344) 200 (66–459) 152 (38–711)
F VIII (IU/dL) 112 (37–334) 112 (32–572) 138 (52–462) 198 (54–627) 130 (32–627)
Angina pectoris (N53) (N53) (N56) (N57) (N519)
vWF (IU/dL) 112 (80–193) 181 (123–237) 192 (120–267) 284 (195–447) 199 (80–447)
F VIII (IU/dL) 95 (89–181) 162 (115–244) 156 (69–204) 256 (148–504) 180 (69–504)
Myocardial infarction (N512) (N54) (N58) (N511) (N535)
vWF (IU/dL) 192 (89–363) 178 (145–246) 211 (144–427) 235 (135–475) 205 (89–475)
F VIII (IU/dL) 179 (78–319) 144 (126–153) 185 (106–325) 215 (127–496) 177 (78–496)
Totals (N5151) (N5103) (N5119) (N5102) (N5475)
vWF (IU/dL) 143 (38–415) 147 (64–711) 169 (71–427) 203 (66–475) 158 (38–711)
F VIII (IU/dL) 116 (37–334) 117 (32–572) 145 (52–462) 205 (54–627) 136 (32–627)
Results are given as medians (ranges). Data were log transformed for two-factor ANOVA. vWF plasma levels are: nephropathy effect, F 5 6.13, P 5 0.0004;
CHD effect, F 5 8.65, P 5 0.0002; nephropathy-CHD interaction effect, F 5 0.87, P 5 0.51. F VIII plasma levels are: nephropathy effect, F 5 8.77, P 5 0.0001;
CHD effect, F 5 6.67, P 5 0.001; nephropathy-CHD interaction effect, F 5 0.72, P 5 0.63.
CAG-39 and 59-GGCAACTCTGAGTCTCTT-39 for thy. There were 19 subjects (4%) with angina pectoris
and 35 subjects (7.4%) with myocardial infarction. ThereThr789Ala (Rsa I) in exon 18; 59-AGGGCTTTAGA
TCAGTCACTGTGGCCCT-39 and 59-TGGCCGCGT was no significant association between diabetic nephrop-
athy and CHD (x2 for trend 5 3.10, P 5 0.08). MeanGCACCCTCACTCCACC-39 for Msp I in intron 19;
59-ATGGGGCCCAATGCCCACC-39 and 59-ACCGT plasma cholesterol was 219 6 55 mg/dL. Forty-seven
percent of the patients were smokers, and 53% of pa-CAGAGCTGCGGCGCA-39 for Ala1381Thr (Hph I) in
exon 28. Aliquots of 15 mL were then digested overnight tients were taking antihypertensive agents. The 359 con-
trol subjects were aged 44 6 9 years, and the female tousing 5 units of Rsa I, 10 units of Msp I, or 7.5 units of
Hph I and were visualized on 2% (Rsa I) or 4% agarose male ratio was 48%.
gels (Msp I and Hph I).
von Willebrand factor and factor VIII plasma
concentrations and nephropathy and coronaryStatistical analysis
heart diseaseData were analyzed using the Statview V program
(Abacus Concepts, Inc., Berkley, CA, USA); they are The vWF and F VIII plasma levels are given in Table
1. The plasma vWF and F VIII levels were dependentgiven as means 6 SD or medians (ranges) when variable
distributions were skewed. Plasma vWF and F VIII val- on both nephropathy stages and CHD stages, but there
was no interaction between nephropathy stages andues were log transformed for calculations. The x2 for trend
test was used for the comparison of qualitative variables CHD stages on plasma vWF or F VIII levels (two-factor
ANOVA on vWF levels: nephropathy effect, F 5 6.13,[22], and ANOVA for quantitative variables. As three
polymorphisms were tested repeatedly, a Bonferroni P 5 0.0004; CHD effect, F 5 8.65, P 5 0.0002; nephropa-
thy-CHD interaction, F 5 0.87, P 5 0.51; and on F VIIIcorrection of P values was performed accordingly. Spear-
man’s coefficient (r9) was used for univariate correlation levels: nephropathy effect, F 5 8.77, P 5 0.0001; CHD
effect, F 5 6.67, P 5 0.001; nephropathy-CHD interac-analysis. Logistic regressions were determined using the
Logistic Procedure of SAS software (SAS Statistical tion effect, F 5 0.72, P 5 0.63).
The plasma vWF levels were related to systolic butSoftware, version G; SAS Institute Inc., Cary, NC, USA).
not to diastolic blood pressures (r9 5 0.13, P 5 0.005
and r9 5 0.025, P 5 0.58, respectively); they were related
RESULTS to patient age (r9 5 0.23, P 5 0.0001), the duration to
Patient data retinopathy onset (r9 5 1 0.15, P 5 0.001), and diabetes
duration (r9 5 0.15, P 5 0.001), but not to HbA1c levelsPatients included in the GENEDIAB study have been
(r9 5 0.02, P 5 0.67), although we previously reportedpreviously described [16]. Their mean age was 44 years
that HbA1c was negatively related to diabetes durationand the female to male ratio was 44%. The duration of
(r9 5 20.16, P 5 0.0005) and to the duration to retinopa-type I diabetes ranged from 8 to 55 years (mean 6 sd,
thy onset [16].29 6 10). These 475 diabetic subjects were not different
The genotype distributions of the three vWF genefrom the initial cohort [16]: 32% presented no nephropa-
thy, 22% had incipient nephropathy, 25% had estab- polymorphisms were in Hardy–Weinberg equilibrium in
the entire type I diabetic population and in each of thelished nephropathy, and 21% had advanced nephropa-
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Table 2. Relationship between vWF gene Thr789Ala polymorphism the possible effect of the M2/M1 (Msp I) polymorphism
and plasma vWF and F VIII levels
in the risk for nephropathy, a polytomous regression
Thr789Ala polymorphism analysis was performed, taking the nephropathy stage
Ala/Ala Thr/Ala Thr/Thr as the outcome variable and the following covariates:
(N 5 65) (N 5 213) (N 5 197) P values HbA1c, diabetes duration, CHD stages, plasma total cho-
Plasma vWF:Ag 185 164 149 0.03 lesterol, ACE D allele [16], and M2/M1 vWF alleles.
IU/dL (64–447) (51–415) (38–711) The conclusion was that the vWF Msp I polymorphism
Plasma F VIII:Ag 152 139 130 NS
was not an independent determinant for nephropathyIU/dL (45–469) (32–496) (37–627)
(data not shown).Results are given as medians (ranges). Data were log-transformed for one-
factor ANOVA. There was no association between the Thr789Ala
polymorphism and diabetic nephropathy (Table 3), and
no significant change in Ala789 allele frequencies in the
different groups of diabetic subjects: no nephropathy,
nephropathy groups as well. The vWF plasma levels were 59.6%; incipient, 66.3%; established, 66.3%; and ad-
related to the Thr789Ala polymorphism, with a signifi- vanced nephropathy, 63.7% (x2 for trend 5 1.28, P 5
cant increase of vWF concentrations from the Thr/Thr 0.78). In a two-factor ANOVA test of plasma vWF levels,
homozygotes to the Ala/Ala individuals (ANOVA, P 5 the effects of both Thr789Ala vWF polymorphism and
0.03; Table 2). By contrast, the F VIII levels were not nephropathy stages remained significant (P 5 0.03 and
significantly related to the Thr789Ala polymorphism P 5 0.0001, respectively), but there was no interaction
(ANOVA, P 5 NS; Table 2). No association was found (P 5 0.76). No association was found between nephropa-
between vWF and F VIII plasma levels and either the thy and the Ala1381Thr polymorphism (Table 3). The
Msp I (vWF, F 5 0.37, P 5 0.69; F VIII, F 5 0.25, P 5 Ala1381 allele frequency was not different according to
0.78) or Ala1381Thr polymorphism (vWF, F 5 0.73, P 5 nephropathy stages: no nephropathy, 37.3%; incipient,
0.48; F VIII, F 5 0.35, P 5 0.70). 29.8%; established, 31.8%; and advanced nephropathy,
32.5% (x2 for trend 5 1.41, P 5 0.23).von Willebrand factor gene polymorphisms
distribution in type 1 diabetic patients and controls von Willebrand factor gene polymorphisms and
The Thr789Ala genotype distribution was not differ- coronary heart disease
ent in type 1 diabetic subjects and in healthy controls: It has been previously suggested that plasma vWF
Ala/Ala 68 (14%) versus 61 (17%), Thr/Ala 222 (45%) levels were related to CHD in the general population
versus 167 (47%), and Thr/Thr 202 (41%) versus 131 [11, 12]. As there was a strong relationship between the
(36%; x2 5 2.57, P 5 0.84). The M2/M1 genotype distri- CHD history and plasma vWF in our cohort of type 1
bution was not significantly different in type I diabetic diabetic subjects, we tested for a possible association
subjects compared with healthy controls: M1/M1 48 between CHD and vWF polymorphisms (Table 4). There
(10%) versus 51 (14%), M2/M1 210 (43%) versus 165 was a significant association between the Thr789Ala poly-
(46%), and M2/M2 233 (47%) versus 142 (40%; x2 5 morphism and CHD (x2 for trend 5 11.32, P 5 0.002),
6.91, P 5 0.09). However, the Ala1381Thr genotype dis- with an increased frequency of Ala/Ala genotypes and
tribution was different in type I diabetic patients and in a decreased frequency of Thr/Thr genotypes in diabetic
controls: Ala/Ala 52 (10.5%) versus 62 (17.3%), Ala/Thr subjects with CHD. The prevalence of the Ala789 allele
223 (45.2%) versus 161 (45%), and Thr/Thr 218 (44.2%) was also significantly associated with CHD: 34.5%
versus 135 (37.7%; x2 5 9.22, P 5 0.03). The M2/M1 among patients having no CHD, 52.6% among those
and Ala1381Thr polymorphisms were found in linkage with angina pectoris, and 52.7% among those with myo-
disequilibrium with the Thr789Ala polymorphism (x2 cardial infarction (x2 for trend 5 11.59, P 5 0.002). In
test, Thr789Ala vs. Msp I, P 5 0.0001; Thr789Ala vs. contrast, no significant difference in the genotype distri-
Ala1381Thr, P 5 0.0001; Msp I vs. Ala1381Thr, P 5 butions for M2/M1 and Ala1381Thr polymorphisms
0.0001). could be noticed according to the CHD history in dia-
betic patients. The M1 allele frequency was 31.1% in
von Willebrand factor gene polymorphisms patients without CHD, 34.2% in those with angina pecto-
and nephropathy ris, and 29.7% in those with myocardial infarction (x2
The Msp I polymorphism was weakly associated with for trend 5 0.014, P 5 0.90), and the Ala1381 allele
the stages of nephropathy (x2 for trend 5 5.97, P 5 0.04; frequency was 33.5% in patients without CHD, 28.9%
Table 3). The M1 allele frequency decreased according in those with angina pectoris, and 31.1% in those with
to the nephropathy stages (no nephropathy, 36.6%; in- myocardial infarction (x2 for trend 5 0.33, P 5 0.56).
cipient, 30.8%; established, 27.4%; advanced nephropa- To determine whether the association of the Thr789Ala
polymorphism with CHD patients was independent ofthy, 27.8%; x2 for trend 5 5.99, P 5 0.04). To evaluate
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Table 3. Relationship between vWF gene polymorphisms and nephropathy in type I diabetic patients
Thr789Ala polymorphism Msp I polymorphism Ala1381Thr polymorphism
Ala/Ala Thr/Ala Thr/Thr M1/M1 M2/M1 M2/M2 Ala/Ala Ala/Thr Thr/Thr
Nephropathy N (%) (N 5 68) (N 5 222) (N 5 202) (N 5 48) (N 5 210) (N 5 233) (N 5 52) (N 5 223) (N 5 218)
Absent 28 70 58 19 77 61 21 75 61
(17.95%) (44.87%) (37.18%) (12.10%) (49.04%) (38.86%) (13.38%) (47.77%) (38.85%)
Incipient 12 46 46 7 50 47 7 48 49
(11.54%) (44.23%) (44.23%) (6.73%) (48.08%) (45.19%) (6.73%) (46.15%) (47.12%)
Established 11 63 52 14 40 70 13 53 60
(8.73%) (50%) (41.27%) (11.29%) (32.26%) (56.45%) (10.32%) (42.06%) (47.62%)
Advanced 17 43 46 8 43 55 11 47 48
(16.04%) (40.57%) (43.4%) (7.55%) (40.57%) (51.88%) (10.38%) (44.34%) (45.28%)
Thr789Ala polymorphism was x2 for trend 5 1.24, P 5 0.79. Msp I polymorphism was x2 for trend 5 5.97, P 5 0.04. Ala1381Thr polymorphism: x2 for trend 5
1.44, P 5 0.69.
patient characteristics possibly affecting vWF levels and the risk for diabetic retinopathy. In particular, the differ-
ence in Ala1381Thr vWF polymorphism we observedof classic CHD risk factors, we used the following polyto-
between the diabetic and control groups might be duemous regression analysis. The CHD stage (absent/angina
to proliferative retinopathy in the diabetic subjects. Thispectoris/myocardial infarction) was considered as the
possibility must be tested in future studies.outcome variable, and the following variables were used
Unexpectedly, the present study suggests that theas covariates: HbA1c (divided for each 1% increase),
Thr789Ala polymorphism in the vWF gene (correspond-diabetes duration (divided into tertiles of equal magni-
ing to Thr26Ala in the mature vWF molecule) may betude), nephropathy stages, plasma total cholesterol [di-
an independent risk factor for the development of CHDvided as , or $ 250 mg/dL (6.45 mmol/L)], ACE D
in a French and Belgian type I diabetic population. More-allele [16], and the Ala789 and Thr789 vWF alleles (pre-
over, high vWF concentrations were found in patientsliminary analysis had indicated that CHD was not associ-
carrying the Ala789 allele, and high vWF was previouslyated with sex or smoking habits in the population stud-
reported to be a risk factor for myocardial infarctionied). The vWF Thr789Ala polymorphism was identified
[11, 12]. Interestingly, this vWF gene substitution mayas an independent risk marker for CHD (P 5 0.0008).
have a codominant effect, since we observed an increas-Furthermore, a codominant effect was suggested because
ing risk for CHD from homozygotes Thr/Thr to heterozy-odds ratios were 1.803 (95% CI, 0.876 to 3.707) for het-
gotes Thr/Ala up to a maximal risk for homozygoteserozygotes and 4.261 (95% CI, 1.821 to 9.968) for Ala789
Ala/Ala.homozygotes, compared with Thr789 homozygotes.
The primary objective of the GENEDIAB study wasOther significant independent risk markers for CHD
to examine candidate genes for diabetic nephropathy,were diabetes duration, nephropathy stage, total choles-
and not for CHD in type I diabetic patients. Thus, theterol, and the ACE D allele. Using this model, the con-
positive finding of this study—that is, an association be-cordance between the observed and predicted severity
tween CHD and the Thr789Ala vWF polymorphism—of CHD was 73.4%.
results from a secondary analysis. However, several ele-
ments support that this finding is not biased by the
DISCUSSION recruitment procedure. The methods used to character-
Our major goal was to address a possible implication ize CHD in the studied patients were similar to those
of vWF as a genetic determinant for diabetic kidney used in other genetic and/or epidemiologic studies of
disease. We detected no independent association be- complications in type I diabetic patients [23]. The preva-
tween any vWF gene polymorphism and nephropathy. lence of CHD was similar to that found in type I diabetic
Therefore, it seems unlikely that the vWF gene plays a subjects of similar age and diabetes duration [23]. Finally,
major role in the development of diabetic nephropathy a survival bias is probably minimal in this study because
in our specific population. However, this study was per- most of the patients were French, and therefore dis-
formed on highly selected type I diabetic subjects charac- played a baseline, absolute risk for CHD that was very
terized by proliferative retinopathy and a long duration low compared with other Westernized populations [24].
of type I diabetes. Hence, it is now worth testing the As we used very specific methods to identify CHD (and
relationship between diabetic nephropathy and vWF not sensitive ones as for a study designed specifically to
polymorphisms in a more general population of type I detect “silent ischemia” in type I diabetes), the probabil-
diabetic subjects. Also, from the present data, we could ity for a type 2 error in identifying a new risk factor for
CHD in type I diabetes was negligible. Rather, we maynot exclude a possible role of vWF polymorphism on
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Table 4. Relationship between vWF gene polymorphisms and CHD in type I diabetic patients
Thr789Ala polymorphism Msp I polymorphism Ala1381Thr polymorphism
Ala/Ala Thr/Ala Thr/Thr M1/M1 M2/M1 M2/M2 Ala/Ala Ala/Thr Thr/Thr
CHD N (%) (N 5 68) (N 5 222) (N 5 202) (N 5 48) (N 5 210) (N 5 233) (N 5 52) (N 5 223) (N 5 218)
Absent 53 195 188 43 185 207 47 199 191
(12.16%) (44.72%) (43.12%) (9.88%) (42.53%) (47.59%) (10.76%) (45.54%) (43.70%)
Angina pectoris 4 10 5 3 7 9 2 7 10
(21.05%) (52.63%) (26.32%) (15.79%) (36.84%) (47.37%) (10.53%) (36.84%) (52.63%)
Myocardial 11 17 9 2 18 17 3 17 17
infarction (29.73%) (45.95%) (24.32%) (5.41%) (48.65%) (45.94%) (8.10%) (45.95%) (45.95%)
Thr789Ala polymorphism was: x2 for trend, 11.32, P 5 0.002. Msp I polymorphism was: x2 for trend, 0.014, P 5 0.90. Ala1381Thr polymorphism was: x2 for trend,
0.34, P 5 0.56.
have underscored the link between the Thr789Ala vWF F VIII [28]. This may suggest that a defect of the F VIII-
vWF interaction might represent a pathophysiologicalpolymorphism and CHD through the present study.
Other studies designed to analyze CHD in type I diabetes mechanism contributing to CHD in diabetic patients, for
instance by enhancing the availability of F VIII at sitesmust be done now to confirm our present data.
The observed association between high vWF levels of thrombus formation. However, the in vitro expression,
in mammalian cells (COS cells), of recombinant vWFand the Ala789 allele is the first description of a “func-
tional” effect of one of the numerous polymorphisms in harboring the Ala789 substitution did not alter the re-
combinant vWF expression level nor its interaction withthe vWF gene coding regions on plasma vWF levels. It
would be of interest to determine whether this effect is F VIII [29]. These data suggest that the Thr789Ala sub-
stitution may not be the real functional variant associatedrestricted to patients with the diabetes phenotype or if
it could be generalized to nondiabetic subjects as well. It with CHD, but a marker of this variant. As the Ala789
allele is associated with increased vWF levels in theis possible that the vWF gene Thr789Ala polymorphism
have only modest effects on vWF levels in the absence whole type I diabetic patient cohort, we could speculate
that a functional variant, in linkage disequilibrium withof chronic hyperglycemia. Alternatively, insulin levels
in the systemic circulation, as provoked by exogenous this allele, may be present in the vWF regulatory se-
quences rather than within regions directly adjacent toinsulin injected to type I diabetic patients, might play a
role in vWF levels. In this regard, high insulin concentra- the Thr789Ala polymorphism position. Indeed, the
SSCP screening of exons 18 to 20 has been performedtions, a risk factor for CHD in the general population,
were found to be an independent predictor of high vWF so far and did not reveal any sequence alteration in these
exons (data not shown). On the other hand, recent dataplasma concentrations in type II diabetes [25].
Both vWF and F VIII levels were increased in our suggested that circulating levels of vWF may be deter-
mined, at least in part, by polymorphic variation in thecohort of type I diabetic subjects with diabetic nephropa-
thy, which is in agreement with previous studies [7, 8]. promoter region of the vWF gene and that this associa-
tion may be mediated by differential binding of nuclearAs all subjects had a severe retinopathy, that suggests
that the vWF increase is associated with kidney disease proteins involved in the regulation of vWF gene expres-
sion [30].per se and is not due to the more general diabetic micro-
vascular disease. It is noteworthy that the vWF levels Besides acting as a carrier of F VIII, vWF promotes
platelet adhesion under high shear rate. It is noteworthywere not different in O and non-O blood group diabetic
subjects (data not shown). This discrepancy between our that increased shear stress conditions have been reported
in type I diabetes resulting from elevated microvasculardata and previous studies [26, 27] may be related to the
presence of proliferative diabetic retinopathy. Indeed, pressure and flow [31]. These alterations could therefore
enhance thrombus formation via the vWF–platelet inter-diabetic retinopathy is associated with elevated plasma
vWF concentrations [9, 10], and this effect of retinopathy action. Platelet adhesion and aggregation studies per-
formed under experimental flow conditions on bloodon vWF might overshadow in our population the in-
terblood group variations of vWF levels generally ob- from type I diabetic subjects did not reveal any enhanced
platelet reactivity [32]. However, this in vitro study wasserved.
The Thr789Ala polymorphism (exon 18) is located performed in a small cohort of type I diabetic patients
(among which only 3 subjects presented CHD), whichwithin the vWF region involved in the binding of vWF
with F VIII (exons 18 to 20). Several naturally occurring may not be representative of all type I diabetic patients
with the full pattern of diabetic vascular alterations.functional variants have been characterized in this re-
gion, which all result in a decrease of vWF affinity for In conclusion, this study suggests that the elevated
Lacquemant et al: vWF and nephropathy in type I diabetes 1443
12. Thompson SG, Kienast J, Pyke SDM, Haverkate F, van de LoovWF levels in type I diabetic patients with nephropathy
JCW: Hemostatic factors and the risk of myocardial infarctionare likely to be a secondary event, possibly because of or sudden death in patients with angina pectoris. N Engl J Med
the renal endothelial dysfunction. However, the common 332:635–641, 1995
13. Borch-Johnsen K, Kreiner S: Proteinuria: Value as predictor ofpolymorphism Thr789Ala in the vWF gene may contrib-
cardiovascular mortality in insulin-dependent diabetes. Br Med Jute to the higher risk for CHD in type I diabetes with 294:1651–1654, 1987
microvascular complications, probably by increasing the 14. Myrup B, Mathiesen ER, Ronn B, Deckert T: Endothelial func-
tion and serum lipids in the course of developing microalbuminuriavWF plasma levels. In this regard, the Thr789Ala poly-
in insulin-dependent diabetes mellitus. Diabetes Res 26:33–39, 1994morphism appears to be a new and independent risk
15. Stehouwer CDA, Fischer HRA, van Kuijk AWR, Polak BCP,
factor for CHD (odds ratio 4.2 for homozygotes), to- Donker AJM: Endothelial dysfunction precedes development of
microalbuminuria in IDDM. Diabetes 44:561–564, 1995gether with a long duration of diabetes, the presence of
16. Marre M, Jeunemaitre X, Gallois Y, Rodier M, Chatellier G,nephropathy, high cholesterol levels, and the D allele
Sert C, Dusselier L, Kahal Z, Chaillous L, Halimi S, Muller
of the angiotensin converting enzyme gene insertion/ A, Sackman H, Bauduceau B, Bled F, Passa Ph, Alhenc-Gelas
deletion polymorphism. F: Contribution of genetic polymorphism in the renin-angiotensin
system to the development of renal complications in insulin-depen-
dent diabetes. J Clin Invest 99:1585–1595, 1997
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